The Association Between Transfer Coefficient of the Lung and the Risk of Exacerbation in Asthma-COPD Overlap: an Observational Cohort Study

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2022 Jan 12

PMID 35016668

Authors

Hiroaki Ogata

Katsuyuki Katahira

Aimi Enokizu-Ogawa

Yujiro Jingushi

Akiko Ishimatsu

Kazuhito Taguchi

Hiroko Nogami

Hiroshi Aso

Atsushi Moriwaki

Makoto Yoshida

Affiliations

Soon will be listed here.

Abstract

Background: Asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO) patients experience exacerbations more frequently than those with asthma or COPD alone. Since low diffusing capacity of the lung for carbon monoxide (D) is known as a strong risk factor for severe exacerbation in COPD, D or a transfer coefficient of the lung for carbon monoxide (K) is speculated to also be associated with the risk of exacerbations in ACO.

Methods: This study was conducted as an observational cohort survey at the National Hospital Organization Fukuoka National Hospital. D and K were measured in 94 patients aged ≥ 40 years with a confirmed diagnosis of ACO. Multivariable-adjusted hazard ratios (HRs) for the exacerbation-free rate over one year were estimated and compared across the levels of D and K.

Results: Within one year, 33.3% of the cohort experienced exacerbations. After adjustment for potential confounders, low K (< 80% per predicted) was positively associated with the incidence of exacerbation (multivariable-adjusted HR = 3.71 (95% confidence interval 1.32-10.4)). The association between low D (< 80% per predicted) and exacerbations showed similar trends, although it failed to reach statistical significance (multivariable-adjusted HR = 1.31 (95% confidence interval 0.55-3.11)).

Conclusions: Low K was a significant risk factor for exacerbations among patients with ACO. Clinicians should be aware that ACO patients with impaired K are at increased risk of exacerbations and that careful management in such a population is mandatory.

References

Bhatt S, Balte P, Schwartz J, Cassano P, Couper D, Jacobs Jr D . Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019; 321(24):2438-2447. PMC: 6593636. DOI: 10.1001/jama.2019.7233. View

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

Soriano J, Lamprecht B, Ramirez A, Martinez-Camblor P, Kaiser B, Alfageme I . Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med. 2015; 3(6):443-50. DOI: 10.1016/S2213-2600(15)00157-5. View

Zavorsky G, Kim D, McGregor E, Starling J, Gavard J . Pulmonary diffusing capacity for nitric oxide during exercise in morbid obesity. Obesity (Silver Spring). 2008; 16(11):2431-8. DOI: 10.1038/oby.2008.402. View

Burrows B, Kasik J, Niden A, Barclay W . Clinical usefulness of the single-breath pulmonary diffusing capacity test. Am Rev Respir Dis. 1961; 84:789-806. DOI: 10.1164/arrd.1961.84.6.789. View

Alshabanat A, Zafari Z, Albanyan O, Dairi M, Fitzgerald J . Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS One. 2015; 10(9):e0136065. PMC: 4559416. DOI: 10.1371/journal.pone.0136065. View

Mullerova H, Maselli D, Locantore N, Vestbo J, Hurst J, Wedzicha J . Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2014; 147(4):999-1007. DOI: 10.1378/chest.14-0655. View

Santos S, Peinado V, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R . Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002; 19(4):632-8. DOI: 10.1183/09031936.02.00245902. View

Guerra B, Gaveikaite V, Bianchi C, Puhan M . Prediction models for exacerbations in patients with COPD. Eur Respir Rev. 2017; 26(143). PMC: 9489020. DOI: 10.1183/16000617.0061-2016. View

10.

Stanojevic S, Graham B, Cooper B, Thompson B, Carter K, Francis R . Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017; 50(3). DOI: 10.1183/13993003.00010-2017. View

11.

Lee H, Kim J, Lee S, Yoon H, Shim J, Park J . Lower diffusing capacity with chronic bronchitis predicts higher risk of acute exacerbation in chronic obstructive lung disease. J Thorac Dis. 2016; 8(6):1274-82. PMC: 4885959. DOI: 10.21037/jtd.2016.04.66. View

12.

Reddel H, Taylor D, Bateman E, Boulet L, Boushey H, Busse W . An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180(1):59-99. DOI: 10.1164/rccm.200801-060ST. View

13.

Behnia M, Wheatley C, Avolio A, Johnson B . Influence of resting lung diffusion on exercise capacity in patients with COPD. BMC Pulm Med. 2017; 17(1):117. PMC: 5571500. DOI: 10.1186/s12890-017-0454-y. View

14.

Suzuki M, Makita H, Konno S, Shimizu K, Kimura H, Kimura H . Asthma-like Features and Clinical Course of Chronic Obstructive Pulmonary Disease. An Analysis from the Hokkaido COPD Cohort Study. Am J Respir Crit Care Med. 2016; 194(11):1358-1365. DOI: 10.1164/rccm.201602-0353OC. View

15.

Hughes J, Pride N . Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med. 2012; 186(2):132-9. DOI: 10.1164/rccm.201112-2160CI. View

16.

Enache I, Oswald-Mammosser M, Scarfone S, Simon C, Schlienger J, Geny B . Impact of altered alveolar volume on the diffusing capacity of the lung for carbon monoxide in obesity. Respiration. 2010; 81(3):217-22. DOI: 10.1159/000314585. View

17.

. [Guideline of respiratory function tests--spirometry, flow-volume curve, diffusion capacity of the lung]. Nihon Kokyuki Gakkai Zasshi. 2004; Suppl:1-56. View

18.

Pelaia C, Procopio G, Deodato M, Florio O, Maglio A, Sciacqua A . Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Respiration. 2020; 100(2):127-134. DOI: 10.1159/000512064. View

19.

Oppenheimer B, Berger K, Rennert D, Pierson R, Norman R, Rapoport D . Effect of circulatory congestion on the components of pulmonary diffusing capacity in morbid obesity. Obesity (Silver Spring). 2006; 14(7):1172-80. DOI: 10.1038/oby.2006.134. View

20.

Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A . Standardisation of spirometry. Eur Respir J. 2005; 26(2):319-38. DOI: 10.1183/09031936.05.00034805. View